{"name": "EnzymeRx",
 "permalink": "enzymerx",
 "crunchbase_url": "http://www.crunchbase.com/company/enzymerx",
 "homepage_url": "http://www.enzymerx.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@enzymerx.com",
 "phone_number": "(201) 843-4424",
 "description": "Paradigm for Refractory Gout",
 "created_at": "Fri Jun 05 09:58:05 UTC 2009",
 "updated_at": "Mon Jan 04 20:40:11 UTC 2010",
 "overview": "\u003Cp\u003EEnzymeRx! a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role. Our patented formulation of pegylated uricase is designed to have a long half life as well as reduced immunogenicity.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       56],
      "assets/images/resized/0004/6876/46876v1-max-150x150.png"],
     [[250,
       94],
      "assets/images/resized/0004/6876/46876v1-max-250x250.png"],
     [[252,
       95],
      "assets/images/resized/0004/6876/46876v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Tony",
      "last_name": "Fiorino",
      "permalink": "tony-fiorino",
      "image": null}},
   {"is_past": false,
    "title": "Chief Medical Officer",
    "person":
     {"first_name": "John",
      "last_name": "Bomalaski",
      "permalink": "john-bomalaski",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$14M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.enzymerx.com/press_releases/enzymerx_2008_05_28.pdf",
    "source_description": "EnzymeRx Announces Receipt of $14 million Capital Investment and Acquisition of Pegylated Uricase",
    "raised_amount": 14000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 5,
    "funded_day": 28,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Pequot Capital",
         "permalink": "pequot-capital",
         "image":
          {"available_sizes":
            [[[150,
               55],
              "assets/images/resized/0002/9564/29564v1-max-150x150.png"],
             [[250,
               93],
              "assets/images/resized/0002/9564/29564v1-max-250x250.png"],
             [[252,
               94],
              "assets/images/resized/0002/9564/29564v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "17 Arcadian Avenue",
    "address2": "Suite 104",
    "zip_code": "07652",
    "city": "Paramus",
    "state_code": "NJ",
    "country_code": "USA",
    "latitude": 40.9234048,
    "longitude": -74.0838388}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        80],
       "assets/images/resized/0004/6875/46875v1-max-150x150.jpg"],
      [[250,
        134],
       "assets/images/resized/0004/6875/46875v1-max-250x250.jpg"],
      [[450,
        242],
       "assets/images/resized/0004/6875/46875v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}